# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT06513962 ‚öîÔ∏è

**Trial Name**: Triptorelin for the Prevention of Ovarian Damage in Adolesce...  
**Patient**: AK (ID: ayesha_001)  
**Generated**: 2025-11-15T21:55:51.038325  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: TOP_TIER  
**Composite Score**: 0.97/1.00  
**Eligibility Probability**: ~100%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT06513962

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: RECRUITING
‚úÖ Ovarian cancer trial match
‚úÖ No stage restriction (assume eligible)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 5 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~100% (pending biomarkers)

**Semantic Similarity**: 0.000 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~100%  
**Calculation**: No specific restrictions (100% eligible)

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

### **Clinical Analysis: Suitability of NCT06513962 for AK**

**To the Care Team of AK:**

This analysis evaluates the appropriateness of clinical trial NCT06513962 for Ms. Kiani, a 40-year-old female with newly diagnosed, treatment-naive Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC).

**Executive Summary:** This clinical trial is unequivocally not a suitable option for Ms. Kiani. The trial's objective (fertility preservation) is misaligned with her urgent clinical priority (oncologic control of life-threatening disease). Furthermore, she is technically ineligible by age, and logistical barriers are prohibitive. Her focus must remain on the immediate initiation of her standard of care (SOC) therapy.

---

#### **1. Drug Mechanism Fit**

The intervention in this trial, triptorelin, is a Gonadotropin-Releasing Hormone (GnRH) agonist. Its mechanism of action is to induce a temporary, reversible state of ovarian suppression to protect oocytes from the gonadotoxic effects of chemotherapy.

This mechanism has **zero anti-tumor activity** against HGSOC. Ms. Kiani's cancer is a non-hormonally driven epithelial malignancy. Triptorelin will not shrink her tumors, lower her CA-125, or resolve her pleural effusions. Her extensive tumor burden and symptomatic Stage IVB disease require an immediate, potent, and targeted anti-neoplastic regimen. The trial's intervention is purely for supportive care related to a long-term quality-of-life outcome (fertility), which is a secondary, if not tertiary, priority given her current life-threatening clinical situation. Her biomarker status (BRCA-negative, HRD unknown) is irrelevant to the mechanism of triptorelin but is critically important for her overall treatment strategy, particularly regarding maintenance therapy with PARP inhibitors.

#### **2. Location Logistics**

The provided trial metadata indicates **no participating sites in the New York City metropolitan area**. This presents an insurmountable logistical barrier. Ms. Kiani's ECOG 1 status is likely tenuous, maintained only with significant supportive care for her large bilateral pleural effusions. Requiring her to travel out of state for screening, enrollment, and follow-up for a non-therapeutic trial would be clinically unsafe, physically exhausting, and would divert critical time and energy away from her primary cancer treatment at her home institution. Proximity to her established care team at a major NYC center (e.g., Mount Sinai, MSK, NYU) is paramount for managing her high-acuity condition.

#### **3. Risk-Benefit for Ayesha**

A formal risk-benefit assessment reveals a profile that is heavily skewed towards risk with minimal, theoretical benefit.

*   **Benefit:** The sole potential benefit is the preservation of ovarian function. Given her age (40) and the planned aggressive chemotherapy, the likelihood of retaining fertility is already diminished. More importantly, in the context of metastatic HGSOC, the primary goal is maximizing progression-free and overall survival. The prospect of future pregnancy is a distant and, unfortunately, statistically unlikely consideration.
*   **Risks:**
    *   **Treatment Delay:** The most significant risk is a delay in initiating her SOC. The process of trial screening and enrollment could postpone the start of her carboplatin/paclitaxel/bevacizumab regimen. Given her high tumor burden and compromised pulmonary status, any delay could lead to rapid clinical deterioration.
    *   **Added Toxicity:** Triptorelin induces a hypoestrogenic state, causing menopausal symptoms (e.g., hot flashes, mood lability). While generally manageable, these side effects would be an unnecessary additional burden on a patient already dealing with cancer symptoms and impending chemotherapy-related toxicities.
    *   **Clinical Distraction:** Pursuing this trial would distract both the patient and the clinical team from the central, urgent task of controlling her metastatic cancer.

#### **4. Comparison to Standard of Care**

This trial does not represent an alternative to her SOC; it would be an adjunct. Her planned regimen of **Carboplatin + Paclitaxel + Bevacizumab is the evidence-based, appropriate, and life-prolonging standard of care** for her specific clinical situation (newly diagnosed, Stage IVB HGSOC, high tumor burden). Bevacizumab, in particular, is well-indicated to help control malignant effusions.

The trial offers no therapeutic advantage over this SOC. In fact, pursuing it would jeopardize the timely and effective delivery of this critical treatment. Ms. Kiani should unequivocally proceed with her planned SOC without delay.

#### **5. Critical Considerations**

In summary, the following points are critical for Ms. Kiani's care team to consider:

1.  **Clinical Urgency:** Her symptomatic, high-volume disease constitutes an oncologic emergency. The immediate priority is cytoreductive systemic therapy, not fertility preservation.
2.  **Misaligned Therapeutic Goal:** The trial's endpoint (ovarian function) is fundamentally disconnected from the patient's primary need (survival and disease control).
3.  **Ineligibility:** At 40 years of age, Ms. Kiani does not meet the strict inclusion criterion of being "< 40 years of age." She is ineligible for enrollment.
4.  **Next Steps for SOC:** The most important action is to confirm her HRD (Homologous Recombination Deficiency) status from her tumor tissue. This result is essential for planning future maintenance therapy with a PARP inhibitor, which has become a cornerstone of first-line HGSOC management and significantly impacts prognosis.

**Conclusion:** Ms. Kiani should not pursue enrollment in NCT06513962. All efforts should be directed toward initiating her standard of care chemotherapy regimen as soon as medically feasible.

---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~100%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT06513962

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT06513962
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~100%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
* \< 40 years of age at the time of enrollment
* Patient must be a post-menarchal female and report that their initial menstrual period occurred \> 6 months prior to enrollment. (Current menstrual status is not part of the inclusion criteria.)
* Newly diagnosed with first cancer, exclusive of breast cancer.

  * Note: Apart from breast carcinoma, other tumor types originating in the breast are permitted (e.g., sarcoma, lymphoma).
* Planned treatment must include one or more of the following alkylating agents delivered with curative intent: cyclophosphamide, ifosfamide, procarbazine, chlorambucil, carmustine (BCNU), lomustine (CCNU), melphalan, thiotepa, busulfan, nitrogen mustard.
* For patients \< 20 years of age at enrollment, the expected alkylator dose must be ‚â• 4 g/m\^2 cumulative cyclophosphamide equivalent dose (CED). For patients ‚â• 20 years of age at enrollment, any planned alkylator dose is permitted. Eligible patients must receive at least one of the alkylators that contribute to CED.
* All patients and/or their parents or legal guardians must sign a written informed consent.
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met. * Any planned radiation to the pelvis; or cranial radiation ‚â• 30 gray (Gy) to the hypothalamus, inclusive of any total body irradiation (TBI).
* Planned bilateral oophorectomy. Note: A participant's desire to pursue alternative fertility preservation procedures (i.e., embryo, oocyte, or ovarian tissue cryopreservation) will be allowed (and in fact encouraged).
* Congenital syndromes associated with infertility and decreased ovarian reserve at baseline. For example: Turner's Syndrome, Fragile X premutation carriers, Down syndrome, etc.
* Pre-existing seizure disorder, congenital long QT syndrome, pseudotumor cerebri; history of pulmonary embolism, venous thrombosis, or myocardial infarction. Note: Contact study chairs if questions arise about other pre-existing conditions.
* Receipt of long acting (depot) GnRH agonists within 6 months before enrollment. In contrast, subcutaneous GnRH agonist used for oocyte retrieval is not an exclusion; oral and other hormonal contraceptive use is also not an exclusion. Note: Please see protocol for the concomitant therapy restrictions for patients during the study treatment period. See protocol for information about oral and other hormonal contractive use during the study treatment period.
* Prior receipt of systemic chemotherapy. However, steroids and intrathecal chemotherapy are permitted prior to study enrollment.
* Any prior radiation to the pelvis; or cranial radiation ‚â• 30 Gy to the hypothalamus, inclusive of any total body irradiation (TBI).
* Patients who are pregnant are not eligible. A pregnancy test is required for female patients of childbearing potential.
* Lactating females who plan to breastfeed their infants for the duration of triptorelin therapy (24 weeks per dose).
* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of triptorelin therapy (24 weeks per dose).

---

## üìä TRIAL DESCRIPTION

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Helen F Graham Cancer Center** - Newark, Delaware
2. **Medical Oncology Hematology Consultants PA** - Newark, Delaware
3. **Christiana Care Health System-Christiana Hospital** - Newark, Delaware
4. **Hackensack University Medical Center** - Hackensack, New Jersey
5. **Montefiore Medical Center - Moses Campus** - The Bronx, New York

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

‚úÖ No critical biomarker gates identified. Proceed with standard eligibility screening.

---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: üî• **P0 - IMMEDIATE ACTION** (Eligibility: ~100%)

**Next Steps**:
1. **Order biomarker tests** (HER2 IHC, HRD if not done)
2. **Contact trial site** (within 48 hours)
3. **Pre-screen Ayesha** (get on coordinator's radar)
4. **Decision at Week 2**: Enroll if eligible
5. **Prepare medical records** (surgical report, pathology, CA-125 history)

**Expected Timeline**:
- Week 1: Complete L1 chemo (cycle 6)
- Week 2: Biomarker results available
- Week 3: Enroll in trial (if eligible) or proceed with SOC maintenance


---

## üéØ VALUE PROPOSITION

**WIN-WIN SCENARIO**:
- If eligible (100% chance) ‚Üí Access to experimental therapy
- If not eligible ‚Üí Gets proven SOC (PARP or bevacizumab maintenance)
- Either way, Ayesha receives appropriate care

**Risk-Benefit**: Low risk (pre-screening doesn't commit to enrollment), high reward (cutting-edge therapy)

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.000  
**Composite Score**: 0.97 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 1.00, Stage 4: 1.00)  
**LLM Analysis**: Gemini gemini-2.5-pro  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
